



16th Executive Board

12-13 June 2012

WHO Headquarters, Salle D

Geneva, Switzerland

## Draft Resolution n°5

**Action name: *Scaling up access to contemporary diagnostics for tuberculosis (TB) with a focus on HIV-associated TB, drug-resistant TB and early TB case detection: A 'technology push/ demand pull' approach based on economies of scale and innovative interventions***

**Lead organization (s): World Health Organization (WHO) and Cepheid**

Recalling the Board Resolution UNITAID/EB15/SSDP/2012/R8;

Noting the result of actions taken by the Secretariat to explore mechanisms leading to additional price reductions of the contemporary diagnostic for TB, Gene Xpert MTB/RIF (Xpert MTB/RIF), so as to maximize market impact;

Taking into account the outcome of the subsequent PRC review of the clarifications provided by the proponents and of the outcomes of the Secretariat's actions to maximize market impact;

The Board of UNITAID, subject to the availability of funds, authorizes the Executive Director to commit up to: (1) USD 4,100,000 comprising UNITAID's share of a co-funded volume-independent buy-down payment to Cepheid, the sole manufacturer of Xpert MTB/RIF, in order to achieve immediate market impact by securing a price reduction of Xpert MTB/RIF cartridges for all eligible purchasers; and (2) USD 25,900,000 for scaling up access to Xpert MTB/RIF in select countries with a focus on HIV-associated TB, drug-resistant TB and early TB case detection.

**Lead recipients:**

1. WHO
2. Cepheid

**Amount:**

1. Up to USD 25,900,000 for WHO
2. Up to USD 4,100,000 for Cepheid

---

TOTAL: Up to USD 30,000,000

**Date of first disbursement:**

TBD

**Conditions for UNITAID funding support:**

Funding is conditional upon:

Cepheid

1. Signature of a memorandum of understanding between UNITAID, the Bill & Melinda Gates Foundation (BMGF) and the United States Government (USG), detailing the co-payment of the buy-down to Cepheid by these three parties and the related terms (Total buy-down of USD 11,100,000 shared as follows: UNITAID up to USD 4,100,000; USG up to USD 3,500,000; and BMGF up to USD 3,500,000).
2. Signature of a legal agreement between UNITAID and Cepheid, including confirmation of the terms and conditions of the Xpert MTB/RIF cartridge price reduction and the purchasers able to access to this price;

../2

3. Signature of a legal agreement between USG and Cepheid and between BMGF and Cepheid.

WHO

1. Signature of a legal agreement between UNITAID and WHO.
2. Agreement by UNITAID, WHO Stop TB Department and the Stop TB Partnership on the countries in which Xpert will be introduced and/or scaled-up and the quantities of Xpert cartridges and instruments to be supplied to each country.

A handwritten signature in black ink, appearing to read 'P. Douste-Blazy', with a horizontal line extending to the right.

Philippe Douste-Blazy